Clinical Trials

47 enrolled 14 charts

Pancreatic Neoplasms, Colorectal Neoplasms

NCT06113809 2026-05-22

Palbociclib and Pembrolizumab in Sarcoma

8 enrolled

Sarcoma

NCT06551142 2026-05-22

PanTumor-101

845 enrolled

Neoplasms

NCT06704724 2026-05-22

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

Phase 1 Terminated

30 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT06789172 2026-05-22

INVOKE

GastrointestinalHead & NeckSarcomaThoracic

166 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Liposarcoma, Sarcoma, Colorectal Neoplasms, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous, Solitary Fibrous Tumors

NCT03144466 2026-05-20

PAPAYA

Phase 1 Terminated

1 enrolled 7 charts

Gynecologic

Uterine Cervical Neoplasms

NCT05537740 2026-05-20

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

BreastDermatologicHead & NeckThoracic

129 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Recurrence, Triple Negative Breast Neoplasms

NCT06246968 2026-05-20

A Study of Pembrolizumab and Cryoablation in People With Breast Cancer

30 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06806852 2026-05-20

A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

85 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03030378 2026-05-19

Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors

36 enrolled

Neoplasm Metastasis

NCT03530397 2026-05-19

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

400 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

NCT04130542 2026-05-19

Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy

105 enrolled

Neoplasms

NCT05614739 2026-05-19

FORAGER-1

535 enrolled

Genitourinary

Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms, Urologic Neoplasms

NCT04526691 2026-05-15

Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

145 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06462794 2026-05-15

First In Human Study of CX-801 in Advanced Solid Tumors

121 enrolled

Solid Tumor, Adult

NCT07160335 2026-05-15

A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors

DermatologicGenitourinaryThoracic

174 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT07166601 2026-05-15

TITER

77 enrolled

GenitourinaryThoracic

Medullary cystic kidney disease 1, Carcinoma, Non-Small-Cell Lung

NCT07484022 2026-05-15

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

37 enrolled

Genitourinary

Carcinoma, Transitional Cell, Peripheral Nervous System Diseases

NCT05901285 2026-05-14

Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors

48 enrolled

Advanced Solid Tumor

NCT07182591 2026-05-14

A Study of DS5361b in Participants With Advanced Solid Tumors

192 enrolled

Advanced Solid Tumor

NCT07247110 2026-05-14

A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

250 enrolled

Neoplasms

NCT02298959 2026-05-13

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

DermatologicGastrointestinalGenitourinaryGynecologicSarcoma

59 enrolled

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

NCT02359565 2026-05-13

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

71 enrolled

CNSGastrointestinal

Familial ependymoma, Turcot syndrome, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ependymoma, Glioma, Medulloblastoma

NCT05353439 2026-05-13

Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

18 enrolled

Small Cell Lung Carcinoma

NCT05422794 2026-05-13

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

57 enrolled

Triple Negative Breast Neoplasms

NCT05673200 2026-05-13

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

32 enrolled

Triple Negative Breast Neoplasms

NCT06439836 2026-05-13

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

27 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT02998567 2026-05-12

HyPeR

60 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04354246 2026-05-12

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

GastrointestinalGynecologicHead & NeckPlasma cellThoracic

94 enrolled

Squamous Cell Carcinoma of Head and Neck, Colonic Neoplasms, Lung Neoplasms, Multiple Myeloma, Ovarian Neoplasms, Neoplasms, Plasma Cell

NCT05492682 2026-05-12

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

BreastDermatologicGastrointestinalSarcomaThoracic

15 enrolled

Carcinoma, Non-Small-Cell Lung, Melanoma, Sarcoma, Osteosarcoma, Sarcoma, Synovial, Colorectal Neoplasms, Liposarcoma, Myxoid, Triple Negative Breast Neoplasms

NCT04389632 2026-05-11

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

1,006 enrolled

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT05581004 2026-05-11

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

450 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms

NCT03932409 2026-05-08

FIERCE

45 enrolled

Gynecologic

Endometrial Neoplasms

NCT05954312 2026-05-08

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

290 enrolled

Adenocarcinoma Of Esophagus, Neoplasms

NCT06004245 2026-05-08

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

280 enrolled

Phase 1 Not yet recruiting

Colorectal Neoplasms, Microsatellite Instability

NCT07300475 2026-05-07

Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients

30 enrolled

Triple Negative Breast Neoplasms

NCT05365581 2026-05-05

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer

398 enrolled

Adenocarcinoma

NCT06057038 2026-05-05

A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors

42 enrolled

Malignant Solid Tumor

NCT06343402 2026-05-05

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

350 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06480552 2026-05-04

An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

240 enrolled

Phase 1 Enrolling by invitation

Advanced Solid Tumors

NCT07218003 2026-05-04

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

149 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Esophageal Squamous Cell Carcinoma, Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT02837263 2026-05-01

PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer

15 enrolled 17 charts

Colorectal Neoplasms

NCT06600321 2026-05-01

A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma

158 enrolled

Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms

NCT05359445 2026-04-30

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

95 enrolled

Neoplasms, Recurrence

NCT05378425 2026-04-30

A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab

90 enrolled